For research use only. Not for therapeutic Use.
Satraplatin (CAT: I001135) is a platinum-based antineoplastic agent that is being investigated for the treatment of advanced prostate cancer in patients who have previously undergone chemotherapy. It belongs to the class of drugs known as platinum analogs, which exert their anticancer effects by forming covalent bonds with DNA, leading to DNA damage and ultimately inhibiting cancer cell growth.
| Catalog Number | I001135 |
| CAS Number | 129580-63-8 |
| Synonyms | BMS182751; BMY45594; JM216; |
| Molecular Formula | C10H22Cl2N2O4Pt |
| Purity | ≥95% |
| Target | DNA Alkylator/Crosslinker |
| Solubility | DMSO: ≥ 33 mg/mL |
| Storage | Store at -20°C |
| Overview of Clinical Research | <span style=”font-family:arial,helvetica,sans-serif;”><span style=”color:#000000;”><span style=”font-size:12px;”>Satraplatin is a <span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>DNA cross linking agent and a DNA synthesis inhibitor. </span><span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>No recent reports of development identified for phase-I development in Prostate-cancer(Neoadjuvant therapy) in China (PO, Capsule).</span></span></span></span> |
| IUPAC Name | (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum |
| InChI | InChI=1S/C6H13N.2C2H4O2.2ClH.H3N.Pt/c7-6-4-2-1-3-5-6;2*1-2(3)4;;;;/h6H,1-5,7H2;2*1H3,(H,3,4);2*1H;1H3;/q;;;;;;+4/p-4 |
| InChIKey | CKNPWBAXEKSCRG-UHFFFAOYSA-J |
| SMILES | [Cl-][Pt+4]([O-]C(C)=O)([O-]C(C)=O)([Cl-])([NH3])[NH2]C1CCCCC1 |
| Reference | 1: Doshi G, Sonpavde G, Sternberg CN. Clinical and pharmacokinetic evaluation of satraplatin. Expert Opin Drug Metab Toxicol. 2012 Jan;8(1):103-11. doi: 10.1517/17425255.2012.636352. Epub 2011 Nov 19. Review. PubMed PMID: 22098065.<br /> |
